Table 3 Nutritional parameters; safety set
Dose-titration phase (n= 39) | Parallel-group phase | ||
|---|---|---|---|
Lanthanum carbonate (n= 10) | Placebo (n= 11) | ||
Weight, kg | |||
Start of dose-titration phase | 76.2 (14.1) | – | – |
Start of parallel-group phase | 74.9 (13.5)a | 73.2 (16.0) | 74.1 (12.0) |
End of parallel-group phase | – | 73.2 (17.0) | 73.4 (13.6)b |
Total serum protein, g/dl | |||
Start of dose-titration phase | 6.9 (0.8) | 6.7 (1.0) | 6.9 (0.7) |
Start of parallel-group phase | 6.8 (0.7)c | 6.6 (0.9) | 6.9 (0.4) |
End of parallel-group phase | – | 6.9 (0.7) | 6.7 (0.7)d |
Serum albumin, g/dl | |||
Start of dose-titration phase | 3.8 (0.4) | 3.7 (0.4) | 4.0 (0.3) |
Start of parallel-group phase | 3.7 (0.3)c | 3.6 (0.4) | 3.9 (0.3) |
End of parallel-group phase | – | 3.7 (0.4) | 3.6 (0.4)e |